Berger Montague Investigates Claims for Telix Pharmaceuticals After Class Action Filing

"Berger Montague PC is investigating claims on behalf of investors who purchased Telix Pharmaceuticals Ltd. (NASDAQ: TLX) securities between Feb. 21 and Aug. 28, 2025, following a class action alleging the company overstated progress on prostate cancer therapeutics and misrepresented its supply chain and partners. Investors may seek lead-plaintiff status by Jan. 9, 2026."

Berger Montague PC represented investors who purchased securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) in connection with a recently filed class action. A class action complaint alleges that, during the period from February 21, 2025 through August 28, 2025, Telix made false or misleading statements and/or failed to disclose material information. The complaint asserts the company overstated its progress with prostate cancer therapeutic candidates and exaggerated the quality of its supply chain and partners, rendering statements about Telix’s business, operations and prospects false, misleading, or without reasonable basis. According to the filing, when the true state of the company’s business was revealed, investors suffered significant losses. Telix is headquartered in Melbourne, Australia, and develops diagnostic and therapeutic radiopharmaceutical products. Investors who purchased Telix securities during the class period may seek appointment as lead plaintiff no later than January 9, 2026. Berger Montague PC represented investors in the Telix Pharmaceuticals securities action with a team composed by: Andrew Abramowitz — Senior Counsel; Caitlin Adorni — Director of Portfolio and Institutional Client Monitoring Services.

Berger Montague Investigates Claims for Telix Pharmaceuticals After Class Action Filing

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads